(sih-ROH-lih-mus PROH-teen-bownd PAR-tih-kulz)
This page contains brief information about sirolimus protein-bound particles and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Sirolimus protein-bound particles are approved to treat adults with:
- Perivascular epithelioid cell tumors that are metastatic or cannot be removed by surgery.
Sirolimus protein-bound particles are a form of sirolimus contained in nanoparticles (very tiny particles of protein). The drug is also called nanoparticle albumin-bound rapamycin. This form may work better than other forms of sirolimus and have fewer side effects.
Sirolimus protein-bound particles are also being studied in the treatment of other types of cancer.
More About Sirolimus Protein-Bound Particles
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Sirolimus Protein-Bound Particles – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Clinical Trials Accepting Patients
Find Clinical Trials for Sirolimus Protein-bound Nanoparticles – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
